მე-2 ტიპის დიაბეტი მოზრდილებში

National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. June 2022 [internet publication].სრული ტექსტი

Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323.სრული ტექსტი  აბსტრაქტი

National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. December 2020 [internet publication].სრული ტექსტი

Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-86.სრული ტექსტი  აბსტრაქტი

1. Meigs JB, Muller DC, Nathan DM, et al. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore Longitudinal Study of Aging. Diabetes. 2003 Jun;52(6):1475-84.სრული ტექსტი  აბსტრაქტი

2. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016 Apr 6;387(10027):1513-30.სრული ტექსტი  აბსტრაქტი

3. Magliano DJ, Islam RM, Barr ELM, et al. Trends in incidence of total or type 2 diabetes: systematic review. BMJ. 2019 Sep 11;366:l5003.სრული ტექსტი  აბსტრაქტი

4.  International Diabetes Federation. IDF diabetes atlas - 10th edition. 2021 [internet publication].სრული ტექსტი

5. WHO. Diabetes. Sep 2022 [internet publication].სრული ტექსტი

6. Preis SR, Pencina MJ, Hwang SJ, et al. Trends in cardiovascular disease risk factors in individuals with and without diabetes mellitus in the Framingham Heart Study. Circulation. 2009 Jul 6;120(3):212-20.სრული ტექსტი  აბსტრაქტი

7. Blomster JI, Woodward M, Zoungas S, et al. The harms of smoking and benefits of smoking cessation in women compared with men with type 2 diabetes: an observational analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron modified release Controlled Evaluation) trial. BMJ Open. 2016 Jan 8;6(1):e009668.სრული ტექსტი  აბსტრაქტი

8. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023 Feb 21;147(8):e93-621.სრული ტექსტი  აბსტრაქტი

9. Hansen MB, Jensen ML, Carstensen B. Causes of death among diabetic patients in Denmark. Diabetologia. 2012 Feb;55(2):294-302. აბსტრაქტი

10. Tancredi M, Rosengren A, Svensson AM, et al. Excess mortality among persons with type 2 diabetes. N Engl J Med. 2015 Oct 29;373(18):1720-32.სრული ტექსტი  აბსტრაქტი

11. Desai JR, Vazquez-Benitez G, Xu Z, et al. Who must we target now to minimize future cardiovascular events and total mortality? Lessons from the surveillance, prevention and management of diabetes mellitus (SUPREME-DM) cohort study. Circ Cardiovasc Qual Outcomes. 2015 Sep;8(5):508-16.სრული ტექსტი  აბსტრაქტი

12. Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018 Aug 16;379(7):633-44.სრული ტექსტი  აბსტრაქტი

13. Berkelmans GF, Gudbjörnsdottir S, Visseren FL, et al. Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with type 2 diabetes mellitus. Eur Heart J. 2019 Sep 7;40(34):2899-906. აბსტრაქტი

14. Gregg EW, Zhuo X, Cheng YJ, et al. Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985-2011: a modelling study. Lancet Diabetes Endocrinol. 2014 Nov;2(11):867-74. აბსტრაქტი

15. Nanayakkara N, Curtis AJ, Heritier S, et al. Impact of age at type 2 diabetes mellitus diagnosis on mortality and vascular complications: systematic review and meta-analyses. Diabetologia. 2021 Feb;64(2):275-87.სრული ტექსტი  აბსტრაქტი

16. Yuan S, Larsson SC. An atlas on risk factors for type 2 diabetes: a wide-angled Mendelian randomisation study. Diabetologia. 2020 Nov;63(11):2359-71.სრული ტექსტი  აბსტრაქტი

17. Dhanasekara CS, Ancona D, Cortes L, et al. Association between autism spectrum disorders and cardiometabolic diseases: a systematic review and meta-analysis. JAMA Pediatr. 2023 Mar 1;177(3):248-57.სრული ტექსტი  აბსტრაქტი

18. Mansi IA, Sumithran P, Kinaan M. Risk of diabetes with statins. BMJ. 2023 May 12;381:e071727. აბსტრაქტი

19. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet. 2014 Mar 22;383(9922):1068-83.სრული ტექსტი  აბსტრაქტი

20. Chen C, Cohrs CM, Stertmann J, et al. Human beta cell mass and function in diabetes: recent advances in knowledge and technologies to understand disease pathogenesis. Mol Metab. 2017 Sep;6(9):943-57.სრული ტექსტი  აბსტრაქტი

21. Defronzo RA. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009 Apr;58(4):773-95.სრული ტექსტი  აბსტრაქტი

22. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol. 2006 Mar 21;47(6):1093-100.სრული ტექსტი  აბსტრაქტი

23. DeFronzo RA. Pathogenesis of type 2 diabetes mellitus. Med Clin North Am. 2004 Jul;88(4):787-835, ix. აბსტრაქტი

24. Wormser D, Kaptoge S, Di Angelantonio E, et al; Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011 Mar 26;377(9771):1085-95.სრული ტექსტი  აბსტრაქტი

25. Kahn R, Buse J, Ferrannini E, et al. The metabolic syndrome: time for a critical appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2005 Sep;28(9):2289-304.სრული ტექსტი  აბსტრაქტი

26. Mayer-Davis EJ, Lawrence JM, Dabelea D, et al. Incidence trends of type 1 and type 2 diabetes among youths, 2002-2012. N Engl J Med. 2017 Apr 13;376(15):1419-29.სრული ტექსტი  აბსტრაქტი

27. National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk. September 2017 [internet publication].სრული ტექსტი

28. World Gastroenterology Organisation and International Federation for the Surgery of Obesity and Metabolic Diseases. IFSO-WGO guidelines on obesity. 2023 [internet publication].სრული ტექსტი

29. Schnurr TM, Jakupović H, Carrasquilla GD, et al. Obesity, unfavourable lifestyle and genetic risk of type 2 diabetes: a case-cohort study. Diabetologia. 2020 Jul;63(7):1324-32.სრული ტექსტი  აბსტრაქტი

30. National Institute of Diabetes and Digestive and Kidney Diseases. Diabetes in America. 3rd edition. Bethesda, MD: National Institutes of Health, NIH Pub No. 17-1468; 2018.სრული ტექსტი

31. Hemmingsen B, Gimenez-Perez G, Mauricio D, et al. Diet, physical activity or both for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017 Dec 4;(12):CD003054.სრული ტექსტი  აბსტრაქტი

32. Li Z, Cheng Y, Wang D, et al. Incidence rate of type 2 diabetes mellitus after gestational diabetes mellitus: a systematic review and meta-analysis of 170,139 women. J Diabetes Res. 2020;2020:3076463.სრული ტექსტი  აბსტრაქტი

33. Bardugo A, Bendor CD, Rotem RS, et al. Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study. Lancet Diabetes Endocrinol. 2023 May;11(5):333-44.სრული ტექსტი  აბსტრაქტი

34. American Diabetes Association. Standards of care in diabetes - 2023. Diabetes Care. 2023 Jan;46(suppl 1):S1-291.სრული ტექსტი

35. Rooney MR, Fang M, Ogurtsova K, et al. Global prevalence of prediabetes. Diabetes Care. 2023 Jul 1;46(7):1388-94.სრული ტექსტი  აბსტრაქტი

36. National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. June 2022 [internet publication].სრული ტექსტი

37. Sattar N, Gill JM. Type 2 diabetes in migrant south Asians: mechanisms, mitigation, and management. Lancet Diabetes Endocrinol. 2015 Dec;3(12):1004-16. აბსტრაქტი

38. Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013 Apr;1281:64-91.სრული ტექსტი  აბსტრაქტი

39. Hu FB. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes Care. 2011 Jun;34(6):1249-57.სრული ტექსტი  აბსტრაქტი

40. Shai I, Jiang R, Manson JE, et al. Ethnicity, obesity, and risk of type 2 diabetes in women: a 20-year follow-up study. Diabetes Care. 2006 Jul;29(7):1585-90.სრული ტექსტი  აბსტრაქტი

41. Centers for Disease Control and Prevention. National Diabetes Statistics Report: estimates of diabetes and its burden in the United States. 2022 [internet publication].სრული ტექსტი

42. Menke A, Casagrande S, Geiss L, Cowie CC. Prevalence of and trends in diabetes among adults in the United States, 1988-2012. JAMA. 2015 Sep 8;314(10):1021-9. აბსტრაქტი

43. Shan Z, Li Y, Zong G, et al. Rotating night shift work and adherence to unhealthy lifestyle in predicting risk of type 2 diabetes: results from two large US cohorts of female nurses. BMJ. 2018 Nov 21;363:k4641.სრული ტექსტი  აბსტრაქტი

44. NHS England. NHS diabetes prevention programme (NHS DPP) [internet publication].სრული ტექსტი

45. Diabetes and Nutrition Study Group (DNSG) of the European Association for the Study of Diabetes (EASD). Evidence-based European recommendations for the dietary management of diabetes. Diabetologia. 2023 Jun;66(6):965-85.სრული ტექსტი  აბსტრაქტი

46. Khan TA, Field D, Chen V, et al. Combination of multiple low-risk lifestyle behaviors and incident type 2 diabetes: a systematic review and dose-response meta-analysis of prospective cohort studies. Diabetes Care. 2023 Mar 1;46(3):643-56.სრული ტექსტი  აბსტრაქტი

47. Nabila S, Kim JE, Choi J, et al. Associations between modifiable risk factors and changes in glycemic status among individuals with prediabetes. Diabetes Care. 2023 Mar 1;46(3):535-43.სრული ტექსტი  აბსტრაქტი

48. Schlesinger S, Neuenschwander M, Ballon A, et al. Adherence to healthy lifestyles and incidence of diabetes and mortality among individuals with diabetes: a systematic review and meta-analysis of prospective studies. J Epidemiol Community Health. 2020 May;74(5):481-487. აბსტრაქტი

49. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019 May;42(5):731-54.სრული ტექსტი  აბსტრაქტი

50. LeBlanc EL, Patnode CD, Webber EM, et al; Agency for Healthcare Research and Quality (US). Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: an updated systematic review for the U.S. Preventive Services Task Force. September 2018 [internet publication].სრული ტექსტი  აბსტრაქტი

51. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.სრული ტექსტი  აბსტრაქტი

52. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537-44. აბსტრაქტი

53. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001 May 3;344(18):1343-50.სრული ტექსტი  აბსტრაქტი

54. Knowler WC, Fowler SE, Hamman RF, et al; Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet. 2009 Nov 14;374(9702):1677-86. აბსტრაქტი

55. Balk EM, Earley A, Raman G, et al. Combined diet and physical activity promotion programs to prevent type 2 diabetes among persons at increased risk: a systematic review for the Community Preventive Services Task Force. Ann Intern Med. 2015 Sep 15;163(6):437-51.სრული ტექსტი  აბსტრაქტი

56. Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006 Sep 23;368(9541):1096-105.სრული ტექსტი  აბსტრაქტი

57. Apolzan JW, Venditti EM, Edelstein SL, et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann Intern Med. 2019 May 21;170(10):682-90. აბსტრაქტი

58. Moelands SV, Lucassen PL, Akkermans RP, et al. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018 Dec 28;(12):CD005061.სრული ტექსტი  აბსტრაქტი

59. Hemmingsen B, Sonne DP, Metzendorf MI, et al. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus. Cochrane Database Syst Rev. 2017;(5):CD012204.სრული ტექსტი  აბსტრაქტი

60. Coleman RL, Scott CAB, Lang Z, et al. Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. Cardiovasc Diabetol. 2019 Oct 17;18(1):135.სრული ტექსტი  აბსტრაქტი

61. Roberts S, Barry E, Craig D, et al. Preventing type 2 diabetes: systematic review of studies of cost-effectiveness of lifestyle programmes and metformin, with and without screening, for pre-diabetes. BMJ Open. 2017 Nov 15;7(11):e017184.სრული ტექსტი  აბსტრაქტი

62. Haw JS, Galaviz KI, Straus AN, et al. Long-term sustainability of diabetes prevention approaches: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2017 Dec 1;177(12):1808-17. აბსტრაქტი

63. Herman WH, Pan Q, Edelstein SL, et al; Diabetes Prevention Program Research Group. Impact of lifestyle and metformin interventions on the risk of progression to diabetes and regression to normal glucose regulation in overweight or obese people with impaired glucose regulation. Diabetes Care. 2017 Dec;40(12):1668-77.სრული ტექსტი  აბსტრაქტი

64. Galaviz KI, Weber MB, Straus A, et al. Global diabetes prevention interventions: a systematic review and network meta-analysis of the real-world impact on incidence, weight, and glucose. Diabetes Care. 2018 Jul;41(7):1526-34.სრული ტექსტი  აბსტრაქტი

65. Armato JP, DeFronzo RA, Abdul-Ghani M, et al. Successful treatment of prediabetes in clinical practice using physiological assessment (STOP DIABETES). Lancet Diabetes Endocrinol. 2018 Oct;6(10):781-9. აბსტრაქტი

66. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019 Sep 10;140(11):e596-e646.სრული ტექსტი  აბსტრაქტი

67. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020 Jan 7;41(2):255-323.სრული ტექსტი  აბსტრაქტი

68. Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019 Sep;104(9):3939-85.სრული ტექსტი  აბსტრაქტი

69. World Health Organization. Classification of diabetes mellitus. 2019 [internet publication].სრული ტექსტი

70. World Health Organisation. HEARTS D: diagnosis and management of type 2 diabetes. 2020 [internet publication].სრული ტექსტი

71. Newton CA, Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med. 2004 Sep 27;164(17):1925-31.სრული ტექსტი  აბსტრაქტი

72. Umpierrez GE, Kitabchi AE. Diabetic ketoacidosis: risk factors and management strategies. Treat Endocrinol. 2003;2(2):95-108. აბსტრაქტი

73. Puttanna A, Padinjakara RNK. Diabetic ketoacidosis in type 2 diabetes mellitus. Pract Diab. 2014;31(4):155-8.სრული ტექსტი

74. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on the risk of diabetic ketoacidosis. April 2016 [internet publication].სრული ტექსტი

75. National Institute for Health and Care Excellence. Type 1 diabetes in adults: diagnosis and management. August 2022 [internet publication].სრული ტექსტი

76. Sacks DB, Arnold M, Bakris GL, et al; National Academy of Clinical Biochemistry. Position statement executive summary: guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Diabetes Care. 2011 Jun;34(6):1419-23.სრული ტექსტი  აბსტრაქტი

77. Lampasona V, Petrone A, Tiberti C, et al. Zinc transporter 8 antibodies complement GAD and IA-2 antibodies in the identification and characterization of adult-onset autoimmune diabetes: Non Insulin Requiring Autoimmune Diabetes (NIRAD) 4. Diabetes Care. 2010 Jan;33(1):104-8.სრული ტექსტი  აბსტრაქტი

78. Newman JD, Berger JS, Ladapo JA. Underuse of medications and lifestyle counseling to prevent cardiovascular disease in patients with diabetes. Diabetes Care. 2019 May;42(5):e75-e76.სრული ტექსტი  აბსტრაქტი

79. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. October 2019​ [internet publication].სრული ტექსტი

80. National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management​. March 2022 [internet publication].სრული ტექსტი

81. Strain WD, Hope SV, Green A, et al. Type 2 diabetes mellitus in older people: a brief statement of key principles of modern day management including the assessment of frailty – a national collaborative stakeholder initiative. Diabet Med. 2018 Jul;35(7):838-45.სრული ტექსტი  აბსტრაქტი

82. Sinclair A, Gallagher A. Managing frailty and associated comorbidities in older adults with diabetes: position statement on behalf of the Association of British Clinical Diabetologists (ABCD). 2019 [internet publication].სრული ტექსტი

83. Strain WD, Down S, Brown P, et al. Diabetes and frailty: an expert consensus statement on the management of older adults with type 2 diabetes. Diabetes Ther. 2021 May;12(5):1227-47.სრული ტექსტი  აბსტრაქტი

84. National Institute for Health and Care Excellence. Chronic kidney disease: assessment and management. November 2021 [internet publication].სრული ტექსტი

85. National Institute for Health and Care Excellence. Peripheral arterial disease: diagnosis and management. December 2020 [internet publication].სრული ტექსტი

86. Anstee QM, McPherson S, Day CP. How big a problem is non-alcoholic fatty liver disease? BMJ. 2011 Jul 18;343:d3897. აბსტრაქტი

87. Norris JM, Johnson RK, Stene LC. Type 1 diabetes-early life origins and changing epidemiology. Lancet Diabetes Endocrinol. 2020 Mar;8(3):226-38.სრული ტექსტი  აბსტრაქტი

88. O'Neal KS, Johnson JL, Panak RL. Recognizing and appropriately treating latent autoimmune diabetes in adults. Diabetes Spectr. 2016 Nov;29(4):249-52.სრული ტექსტი  აბსტრაქტი

89. Naik RG, Brooks-Worrell BM, Palmer JP. Latent autoimmune diabetes in adults. J Clin Endocrinol Metab. 2009 Dec;94(12):4635-44.სრული ტექსტი  აბსტრაქტი

90. Pihoker C, Gilliam LK, Ellard S, et al; SEARCH for Diabetes in Youth Study Group. Prevalence, characteristics and clinical diagnosis of maturity onset diabetes of the young due to mutations in HNF1A, HNF4A, and glucokinase: results from the SEARCH for Diabetes in Youth. J Clin Endocrinol Metab. 2013 Oct;98(10):4055-62.სრული ტექსტი  აბსტრაქტი

91. Nkonge KM, Nkonge DK, Nkonge TN. The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY). Clin Diabetes Endocrinol. 2020 Nov 4;6(1):20.სრული ტექსტი  აბსტრაქტი

92. Fajans SS, Bell GI. MODY: history, genetics, pathophysiology, and clinical decision making. Diabetes Care. 2011 Aug;34(8):1878-84.სრული ტექსტი  აბსტრაქტი

93. Chiang JL, Maahs DM, Garvey KC, et al. Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care. 2018 Sep;41(9):2026-44.სრული ტექსტი  აბსტრაქტი

94. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med. 2001 Sep 27;345(13):971-80. აბსტრაქტი

95. Vellanki P, Umpierrez GE. Diabetic ketoacidosis: a common debut of diabetes among African Americans with type 2 diabetes. Endocr Pract. 2017 Aug;23(8):971-8.სრული ტექსტი  აბსტრაქტი

96. Steenkamp DW, Alexanian SM, Sternthal E. Approach to the patient with atypical diabetes. CMAJ. 2014 Jun 10;186(9):678-84.სრული ტექსტი  აბსტრაქტი

97. National Institute for Health and Care Excellence. Diabetes in pregnancy: management from preconception to the postnatal period. December 2020 [internet publication].სრული ტექსტი

98. UK National Screening Committee. Adult screening programme: diabetes. November 2019 [internet publication].სრული ტექსტი

99. US Preventive Services Task Force. Prediabetes and type 2 diabetes: screening. August 2021 [internet publication].სრული ტექსტი

100. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-86.სრული ტექსტი  აბსტრაქტი

101. Sherifali D, Bai JW, Kenny M, et al. Diabetes self-management programmes in older adults: a systematic review and meta-analysis. Diabet Med. 2015 Nov;32(11):1404-14.სრული ტექსტი  აბსტრაქტი

102. Pillay J, Armstrong MJ, Butalia S, et al. Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis. Ann Intern Med. 2015 Dec 1;163(11):848-60.სრული ტექსტი  აბსტრაქტი

103. Chatterjee S, Davies MJ, Heller S, et al. Diabetes structured self-management education programmes: a narrative review and current innovations. Lancet Diabetes Endocrinol. 2018 Feb;6(2):130-42. აბსტრაქტი

104. Fisher L, Hessler D, Glasgow RE, et al. REDEEM: a pragmatic trial to reduce diabetes distress. Diabetes Care. 2013 Sep;36(9):2551-8.სრული ტექსტი  აბსტრაქტი

105. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014 May;174(5):773-85. აბსტრაქტი

106. Hambling CE, Khunti K, Cos X, et al. Factors influencing safe glucose-lowering in older adults with type 2 diabetes: a PeRsOn-centred ApproaCh To IndiVidualisEd (PROACTIVE) glycemic goals for older people: a position statement of Primary Care Diabetes Europe. Prim Care Diabetes. 2019 Aug;13(4):330-52.სრული ტექსტი  აბსტრაქტი

107. Diabetes UK. Position statement: low carb diets for people with diabetes. May 2021 [internet publication].სრული ტექსტი

108. Snorgaard O, Poulsen GM, Andersen HK, et al. Systematic review and meta-analysis of dietary carbohydrate restriction in patients with type 2 diabetes. BMJ Open Diabetes Res Care. 2017 Feb 23;5(1):e000354.სრული ტექსტი  აბსტრაქტი

109. Goldenberg JZ, Day A, Brinkworth GD, et al. Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ. 2021 Jan 13;372:m4743.სრული ტექსტი  აბსტრაქტი

110. Papamichou D, Panagiotakos DB, Itsiopoulos C. Dietary patterns and management of type 2 diabetes: a systematic review of randomised clinical trials. Nutr Metab Cardiovasc Dis. 2019 Jun;29(6):531-43.სრული ტექსტი  აბსტრაქტი

111. Pollakova D, Andreadi A, Pacifici F, et al. The impact of vegan diet in the prevention and treatment of type 2 diabetes: a systematic review. Nutrients. 2021 Jun 21;13(6):2123.სრული ტექსტი  აბსტრაქტი

112. Tosatti JAG, Alves MT, Gomes KB. The role of the mediterranean dietary pattern on metabolic control of patients with diabetes mellitus: a narrative review. Adv Exp Med Biol. 2021;1307:115-28. აბსტრაქტი

113. National Institute for Health and Care Excellence. Preventing excess weight gain. March 2015 [internet publication].სრული ტექსტი

114. National Institute for Health and Care Excellence. Weight management: lifestyle services for overweight or obese adults. May 2014 [internet publication].სრული ტექსტი

115. National Institute for Health and Care Excellence. Obesity: identification, assessment and management. July 2023 [internet publication].სრული ტექსტი

116. National Institute for Health and Care Excellence. Physical activity: brief advice for adults in primary care. May 2013 [internet publication].სრული ტექსტი

117. Rietz M, Lehr A, Mino E, et al. Physical activity and risk of major diabetes-related complications in individuals with diabetes: a systematic review and meta-analysis of observational studies. Diabetes Care. 2022 Dec 1;45(12):3101-11.სრული ტექსტი  აბსტრაქტი

118. Lean ME, Leslie WS, Barnes AC, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018 Feb 10;391(10120):541-51. აბსტრაქტი

119. Gregg EW, Chen H, Wagenknecht LE, et al; Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012 Dec 19;308(23):2489-96.სრული ტექსტი  აბსტრაქტი

120. Lean ME, Leslie WS, Barnes AC, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019 May;7(5):344-55. აბსტრაქტი

121. NHS England. NHS to expand soups and shakes for people with type 2 diabetes​. April 2023 [internet publication].სრული ტექსტი

122. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring and pharmacist management on blood pressure control: a cluster randomized clinical trial. JAMA. 2013 Jul 3;310(1):46-56.სრული ტექსტი  აბსტრაქტი

123. National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. May 2023 [internet publication].სრული ტექსტი

124. Giugliano RP, Cannon CP, Blazing MA, et al; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2018 Apr 10;137(15):1571-82. აბსტრაქტი

125. Sabatine MS, Giugliano RP, Keech AC, et al; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017 May 4;376(18):1713-22.სრული ტექსტი  აბსტრაქტი

126. Squizzato A, Suter MB, Nerone M, et al. PCSK9 inhibitors for treating dyslipidemia in patients at different cardiovascular risk: a systematic review and a meta-analysis. Intern Emerg Med. 2017 Oct;12(7):1043-53. აბსტრაქტი

127. Lee YJ, Cho JY, You SC, et al. Moderate-intensity statin with ezetimibe vs. high-intensity statin in patients with diabetes and atherosclerotic cardiovascular disease in the RACING trial. Eur Heart J. 2023 Mar 14;44(11):972-83.სრული ტექსტი  აბსტრაქტი

128. National Institute for Health and Care Excellence. Tobacco: preventing uptake, promoting quitting and treating dependence. January 2023 [internet publication].სრული ტექსტი

129. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.სრული ტექსტი  აბსტრაქტი

130. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021 Sep 7;42(34):3227-337.სრული ტექსტი  აბსტრაქტი

131. ASCEND Study Collaborative Group; Bowman L, Mafham M, Wallendszus K, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018 Oct 18;379(16):1529-39.სრული ტექსტი  აბსტრაქტი

132. National Institute for Health and Care Excellence. Finerenone for treating chronic kidney disease in type 2 diabetes. March 2023 [internet publication].სრული ტექსტი

133. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 Clinical Practice Guideline for diabetes management in chronic kidney disease. Kidney Int. 2022 Nov;102(5s):S1-127.სრული ტექსტი  აბსტრაქტი

134. Laiteerapong N, Cooper JM, Skandari MR, et al. Individualized glycemic control for US adults with type 2 diabetes: a cost-effectiveness analysis. Ann Intern Med. 2018 Feb 6;168(3):170-8. აბსტრაქტი

135. Ismail-Beigi F, Moghissi E, Tiktin M, et al. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med. 2011 Apr 19;154(8):554-9. აბსტრაქტი

136. Driver and Vehicle Licensing Agency. Information for drivers with diabetes. June 2021 [internet publication].სრული ტექსტი

137. Lewis DM, Oser TK, Wheeler BJ. Continuous glucose monitoring. BMJ. 2023 Mar 3;380:e072420. აბსტრაქტი

138. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854-65. აბსტრაქტი

139. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89.სრული ტექსტი  აბსტრაქტი

140. Patel A, MacMahon S, et al; ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008 Jun 6;358(24):2560-72.სრული ტექსტი  აბსტრაქტი

141. Gerstein HC, Miller ME, Byington RP, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 12;358(24):2545-59.სრული ტექსტი  აბსტრაქტი

142. Li S, Vandvik PO, Lytvyn L, et al. SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline. BMJ. 2021 May 11;373:n1091.სრული ტექსტი  აბსტრაქტი

143. Griffin SJ, Leaver JK, Irving GJ. Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. Diabetologia. 2017 Sep;60(9):1620-9.სრული ტექსტი  აბსტრაქტი

144. Gerstein HC, Miller ME, Genuth S, et al; ACCORD Study Group. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011 Mar 3;364(9):818-28. აბსტრაქტი

145. Reaven PD, Emanuele NV, Wiitala WL, et al; VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med. 2019 Jun 6;380(23):2215-24.სრული ტექსტი  აბსტრაქტი

146. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39.სრული ტექსტი  აბსტრაქტი

147. Abrilla AA, Pajes ANNI, Jimeno CA. Metformin extended-release versus metformin immediate-release for adults with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Diabetes Res Clin Pract. 2021 Aug;178:108824.სრული ტექსტი  აბსტრაქტი

148. National Institute for Health and Care Excellence. ​Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. May 2016 [internet publication].სრული ტექსტი

149. National Institute for Health and Care Excellence. Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes. March 2019 [internet publication].სრული ტექსტი

150. Herrington WG, Frankel AH. UK Kidney Association clinical practice guideline: sodium-glucose co-transporter-2 (SGLT-2) inhibition in adults with kidney disease. Oct 2021 [internet publication]. სრული ტექსტი

151. National Institute for Health and Care Excellence. Canagliflozin in combination therapy for treating type 2 diabetes. June 2014 [internet publication].სრული ტექსტი

152. National Institute for Health and Care Excellence. Empagliflozin in combination therapy for treating type 2 diabetes. March 2015 [internet publication].სრული ტექსტი

153. National Institute for Health and Care Excellence. Dapagliflozin in combination therapy for treating type 2 diabetes. Nov 2016 [internet publication].სრული ტექსტი

154. National Institute for Health and Care Excellence. Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes. June 2019 [internet publication].სრული ტექსტი

155. National Institute for Health and Care Excellence. Dapagliflozin in triple therapy for treating type 2 diabetes. November 2016 [internet publication].სრული ტექსტი

156. Medicines and Healthcare products Regulatory Agency. Insulin combined with pioglitazone: risk of cardiac failure. December 2014 [internet publication].სრული ტექსტი

157. Medicines and Healthcare products Regulatory Agency. GLP-1 receptor agonists: reports of diabetic ketoacidosis when concomitant insulin was rapidly reduced or discontinued. June 2019 [internet publication].სრული ტექსტი

158. Tsapas A, Karagiannis T, Kakotrichi P, et al. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Obes Metab. 2021 Sep;23(9):2116-24.სრული ტექსტი  აბსტრაქტი

159. Tsapas A, Avgerinos I, Karagiannis T, et al. Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis. Ann Intern Med. 2020 Aug 18;173(4):278-86.სრული ტექსტი  აბსტრაქტი

160. Monami M, Candido R, Pintaudi B, et al. Effect of metformin on all-cause mortality and major adverse cardiovascular events: an updated meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021 Mar 10;31(3):699-704.სრული ტექსტი  აბსტრაქტი

161. de Boer IH, Khunti K, Sadusky T, et al. Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving global outcomes (KDIGO). Diabetes Care. 2022 Dec 1;45(12):3075-90.სრული ტექსტი  აბსტრაქტი

162. Medicines and Healthcare products Regulatory Agency. Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk. June 2022 [internet publication].სრული ტექსტი

163. Scheen AJ. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs. 2015 Jan;75(1):33-59. აბსტრაქტი

164. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021 Jan 13;372:m4573.სრული ტექსტი  აბსტრაქტი

165. Zelniker TA, Wiviott SD, Raz I, et al. Comparison of the effects of glucagon-like peptide receptor agonists and sodium-glucose cotransporter 2 inhibitors for prevention of major adverse cardiovascular and renal outcomes in type 2 diabetes mellitus. Circulation. 2019 Apr 23;139(17):2022-31. აბსტრაქტი

166. Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017 Aug 17;377(7):644-57.სრული ტექსტი  აბსტრაქტი

167. Cherney DZ, Zinman B, Inzucchi SE, et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017 Aug;5(8):610-21. აბსტრაქტი

168. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019 Aug 27;140(9):739-50.სრული ტექსტი  აბსტრაქტი

169. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5;393(10166):31-39. აბსტრაქტი

170. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-306.სრული ტექსტი  აბსტრაქტი

171. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28.სრული ტექსტი  აბსტრაქტი

172. Mahaffey KW, Neal B, Perkovic V, et al; CANVAS Program Collaborative Group. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018 Jan 23;137(4):323-34.სრული ტექსტი  აბსტრაქტი

173. Rådholm K, Figtree G, Perkovic V, et al. Canagliflozin and heart failure in type 2 diabetes mellitus. Circulation. 2018 Jul 31;138(5):458-68.სრული ტექსტი  აბსტრაქტი

174. Wiviott SD, Raz I, Bonaca MP, et al; DECLARE–TIMI 58 Investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019 Jan 24;380(4):347-57.სრული ტექსტი  აბსტრაქტი

175. Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-54. აბსტრაქტი

176. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019 May 28;139(22):2528-36.სრული ტექსტი  აბსტრაქტი

177. Figtree GA, Rådholm K, Barrett TD, et al. Effects of canagliflozin on heart failure outcomes associated with preserved and reduced ejection fraction in type 2 diabetes mellitus. Circulation. 2019 May 28;139(22):2591-3.სრული ტექსტი  აბსტრაქტი

178. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.სრული ტექსტი  აბსტრაქტი

179. National Institute for Health and Care Excellence. Dapagliflozin for treating chronic heart failure with reduced ejection fraction. February 2021 [internet publication].სრული ტექსტი

180. Vaduganathan M, Docherty KF, Claggett BL, et al. SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials. Lancet. 2022 Sep 3;400(10354):757-67.სრული ტექსტი  აბსტრაქტი

181. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020 Oct 8;383(15):1413-24.სრული ტექსტი  აბსტრაქტი

182. Chen C, Peng H, Li M, et al. Patients with type 2 diabetes mellitus and heart failure benefit more from sodium-glucose cotransporter 2 inhibitor: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2021;12:664533.სრული ტექსტი  აბსტრაქტი

183. Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022 May 10;145(19):1460-70.სრული ტექსტი  აბსტრაქტი

184. Cinti F, Moffa S, Impronta F, et al. Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date. Drug Des Devel Ther. 2017 Oct 3;11:2905-19.სრული ტექსტი  აბსტრაქტი

185. ClinicalTrials.gov. Cardiovascular outcomes following ertugliflozin treatment in type 2 diabetes mellitus participants with vascular disease: the VERTIS CV study (MK-8835-004). April 2019 [internet publication].სრული ტექსტი

186. Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020 Oct 8;383(15):1425-35.სრული ტექსტი  აბსტრაქტი

187. Ueda P, Svanström H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018 Nov 14;363:k4365.სრული ტექსტი  აბსტრაქტი

188. Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015 Sep;38(9):1680-6.სრული ტექსტი  აბსტრაქტი

189. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Sep;38(9):1687-93.სრული ტექსტი  აბსტრაქტი

190. Fleming N, Hamblin PS, Story D, et al. Evolving evidence of diabetic ketoacidosis in patients taking sodium-glucose cotransporter 2 inhibitors. J Clin Endocrinol Metab. 2020 Aug 1;105(8):dgaa200.სრული ტექსტი  აბსტრაქტი

191. US Food and Drug Administration (FDA). FDA drug safety communication: FDA strengthens kidney warnings for diabetes medicines canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR). June 2016 [internet publication].სრული ტექსტი

192. European Medicines Agency. SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information. February 2017 [internet publication].სრული ტექსტი

193. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes). March 2017 [internet publication].სრული ტექსტი

194. Dorsey-Treviño EG, González-González JG, Alvarez-Villalobos N, et al. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. J Endocrinol Invest. 2020 Mar;43(3):289-304. აბსტრაქტი

195. US Food and Drug Administration. FDA drug safety communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. August 2018 [internet publication].სრული ტექსტი

196. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum). February 2019 [internet publication].სრული ტექსტი

197. Giugliano D, Scappaticcio L, Longo M, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021 Sep 15;20(1):189.სრული ტექსტი  აბსტრაქტი

198. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-30. აბსტრაქტი

199. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016 Nov 10;375(19):1834-44.სრული ტექსტი  აბსტრაქტი

200. Kaul S. Mitigating cardiovascular risk in type 2 diabetes with antidiabetes drugs: a review of principal cardiovascular outcome results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 trials. Diabetes Care. 2017 Jul;40(7):821-31.სრული ტექსტი  აბსტრაქტი

201. Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016 Jul 28;375(4):311-22.სრული ტექსტი  აბსტრაქტი

202. Hu Y. Advances in reducing cardiovascular risk in the management of patients with type 2 diabetes mellitus. Chronic Dis Transl Med. 2019 Mar 15;5(1):25-36.სრული ტექსტი  აბსტრაქტი

203. Yuan D, Sharma H, Krishnan A, et al. Effect of glucagon-like peptide 1 receptor agonists on albuminuria in adult patients with type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetes Obes Metab. 2022 Sep;24(9):1869-81.სრული ტექსტი  აბსტრაქტი

204. Ferreira JP, Saraiva F, Sharma A, et al. Glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes with and without chronic heart failure: a meta-analysis of randomized placebo-controlled outcome trials. Diabetes Obes Metab. 2023 Jun;25(6):1495-502.სრული ტექსტი  აბსტრაქტი

205. Htike ZZ, Zaccardi F, Papamargaritis D, et al. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis. Diabetes Obes Metab. 2017 Apr;19(4):524-36. აბსტრაქტი

206. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007 Jul 11;298(2):194-206. აბსტრაქტი

207. Konwar M, Bose D, Jaiswal SK, et al. Efficacy and safety of liraglutide 3.0 mg in patients with overweight and obese with or without diabetes: a systematic review and meta-analysis. Int J Clin Pract. 2022;2022:1201977.სრული ტექსტი  აბსტრაქტი

208. Hu W, Song R, Cheng R, et al. Use of GLP-1 Receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2022;13:927859.სრული ტექსტი  აბსტრაქტი

209. Bezin J, Gouverneur A, Pénichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023 Feb 1;46(2):384-90.სრული ტექსტი  აბსტრაქტი

210. Chai S, Yu S, Yang Z, et al. Effect of incretin-based therapies on cancers of digestive system among 101 595 patients with type 2 diabetes mellitus: a systematic review and network meta-analysis combining 84 trials with a median duration of 30 weeks. BMJ Open Diabetes Res Care. 2019;7(1):e000728.სრული ტექსტი  აბსტრაქტი

211. Mannucci E, Nreu B, Montereggi C, et al. Cardiovascular events and all-cause mortality in patients with type 2 diabetes treated with dipeptidyl peptidase-4 inhibitors: an extensive meta-analysis of randomized controlled trials. Nutr Metab Cardiovasc Dis. 2021 Sep 22;31(10):2745-55.სრული ტექსტი  აბსტრაქტი

212. Pradhan R, Yin H, Yu OHY, et al. Incretin-based drugs and the risk of acute liver injury among patients with type 2 diabetes. Diabetes Care. 2022 Oct 1;45(10):2289-98.სრული ტექსტი  აბსტრაქტი

213. He L, Wang J, Li Z, et al. Dipeptidyl peptidase 4 inhibitors and gallbladder or biliary diseases: data from the U.S. Food and Drug Administration adverse event reporting system. Diabetes Care. 2023 Feb 1;46(2):e72-3.სრული ტექსტი  აბსტრაქტი

214. Khunti K, Chatterjee S, Gerstein HC, et al. Do sulphonylureas still have a place in clinical practice? Lancet Diabetes Endocrinol. 2018 Oct;6(10):821-32.სრული ტექსტი  აბსტრაქტი

215. Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019 Sep 24;322(12):1155-66.სრული ტექსტი  აბსტრაქტი

216. Wang H, Cordiner RLM, Huang Y, et al. Cardiovascular safety in type 2 diabetes with sulfonylureas as second-line drugs: a nationwide population-based comparative safety study. Diabetes Care. 2023 May 1;46(5):967-77.სრული ტექსტი  აბსტრაქტი

217. US Food and Drug Administration. FDA drug safety communication: updated FDA review concludes that use of type 2 diabetes medicine pioglitazone may be linked to an increased risk of bladder cancer. December 2016 [internet publication].სრული ტექსტი

218. European Medicines Agency. Questions and answers on the suspension of rosiglitazone-containing medicines (Avandia, Avandamet and Avaglim). September 2010 [internet publication].სრული ტექსტი

219. Wysham CH, Lin J, Kuritzky L. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis. Postgrad Med. 2017 May;129(4):436-45. აბსტრაქტი

220. Maiorino MI, Chiodini P, Bellastella G, et al. Insulin and glucagon-like peptide 1 receptor agonist combination therapy in type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2017 Apr;40(4):614-24.სრული ტექსტი  აბსტრაქტი

221. Aroda VR, Arulandu JR, Cannon AJ. Insulin/glucagon-like peptide-1 receptor agonist combination therapy for the treatment of type 2 diabetes: are two agents better than one? Clin Diabetes. 2018 Apr;36(2):138-47.სრული ტექსტი  აბსტრაქტი

222. Tang H, Cui W, Li D, et al. Sodium-glucose co-transporter 2 inhibitors in addition to insulin therapy for management of type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Diabetes Obes Metab. 2017 Jan;19(1):142-7. აბსტრაქტი

223. Rosenstock J, Jelaska A, Zeller C, et al. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2015 Oct;17(10):936-48.სრული ტექსტი  აბსტრაქტი

224. Rosenstock J, Jelaska A, Frappin G, et al. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes. Diabetes Care. 2014 Jul;37(7):1815-23.სრული ტექსტი  აბსტრაქტი

225. Down S. How to advise on sick day rules. Diabetes Primary Care. 2020 Apr;22(3):47-8.სრული ტექსტი

226. Diabetes Canada. Clinical practice guidelines for the prevention and management of diabetes in Canada: appendix 8 - sick-day medication list. 2018 [internet publication].სრული ტექსტი

227. Carlsson LM, Peltonen M, Ahlin S, et al. Bariatric surgery and prevention of type 2 diabetes in Swedish obese subjects. N Engl J Med. 2012 Aug 23;367(8):695-704.სრული ტექსტი  აბსტრაქტი

228. Schauer PR, Kashyap SR, Wolski K, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med. 2012 Apr 26;366(17):1567-76.სრული ტექსტი  აბსტრაქტი

229. Schauer PR, Bhatt DL, Kirwan JP, et al; STAMPEDE Investigators. Bariatric surgery versus intensive medical therapy for diabetes - 5-year outcomes. N Engl J Med. 2017;376:641-51.სრული ტექსტი  აბსტრაქტი

230. Kashyap SR, Bhatt DL, Wolski K, et al. Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment. Diabetes Care. 2013 Aug;36(8):2175-82.სრული ტექსტი  აბსტრაქტი

231. Ikramuddin S, Korner J, Lee WJ, et al. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013 Jun 5;309(21):2240-9.სრული ტექსტი  აბსტრაქტი

232. Halperin F, Ding SA, Simonson DC, et al. Roux-en-Y gastric bypass surgery or lifestyle with intensive medical management in patients with type 2 diabetes: feasibility and 1-year results of a randomized clinical trial. JAMA Surg. 2014 Jul;149(7):716-26.სრული ტექსტი  აბსტრაქტი

233. Yska JP, van Roon EN, de Boer A, et al. Remission of type 2 diabetes mellitus in patients after different types of bariatric surgery: a population-based cohort study in the United Kingdom. JAMA Surg. 2015 Dec;150(12):1126-33.სრული ტექსტი  აბსტრაქტი

234. Fisher DP, Johnson E, Haneuse S, et al. Association between bariatric surgery and macrovascular disease outcomes in patients with type 2 diabetes and severe obesity. JAMA. 2018 Oct 16;320(15):1570-82.სრული ტექსტი  აბსტრაქტი

235. O'Brien R, Johnson E, Haneuse S, et al. Microvascular outcomes in patients with diabetes after bariatric surgery versus usual care: a matched cohort study. Ann Intern Med. 2018 Sep 4;169(5):300-10. აბსტრაქტი

236. Borgeraas H, Hofsø D, Hertel JK, et al. Comparison of the effect of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2020 Jun;21(6):e13011.სრული ტექსტი  აბსტრაქტი

237. O'Keefe KL, Kemmeter PR, Kemmeter KD. Bariatric surgery outcomes in patients aged 65 years and older at an American Society for Metabolic and Bariatric Surgery Center of Excellence. Obes Surg. 2010 Sep;20(9):1199-205. აბსტრაქტი

238. Park JY. Prediction of type 2 diabetes remission after bariatric or metabolic surgery. J Obes Metab Syndr. 2018 Dec 30;27(4):213-22.სრული ტექსტი  აბსტრაქტი

239. Mahmud N, Panchal S, Abu-Gazala S, et al. Association between bariatric surgery and alcohol use-related hospitalization and all-cause mortality in a veterans affairs cohort. JAMA Surg. 2023 Feb 1;158(2):162-71.სრული ტექსტი  აბსტრაქტი

240. Tinker SC, Gilboa SM, Moore CA, et al. Specific birth defects in pregnancies of women with diabetes: National Birth Defects Prevention Study, 1997-2011. Am J Obstet Gynecol. 2020 Feb;222(2):176.e1-11.სრული ტექსტი  აბსტრაქტი

241. National Institute for Health and Care Excellence. Hypertension in pregnancy: diagnosis and management. April 2023 [internet publication].სრული ტექსტი

242. Sherr JL, Heinemann L, Fleming GA, et al. Automated insulin delivery: benefits, challenges, and recommendations. A Consensus Report of the Joint Diabetes Technology Working Group of the European Association for the Study of Diabetes and the American Diabetes Association. Diabetologia. 2023 Jan;66(1):3-22.სრული ტექსტი  აბსტრაქტი

243. Daly AB, Boughton CK, Nwokolo M, et al. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. Nat Med. 2023 Jan;29(1):203-8.სრული ტექსტი  აბსტრაქტი

244. Crabtree TSJ, Griffin TP, Yap YW, et al. Hybrid closed-loop therapy in adults with type 1 diabetes and above-target HbA1c: a real-world observational study. Diabetes Care. 2023 Oct 1;46(10):1831-8.სრული ტექსტი  აბსტრაქტი

245. Philis-Tsimikas A, Asong M, Franek E, et al. Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial. Lancet Diabetes Endocrinol. 2023 Jun;11(6):414-25.სრული ტექსტი  აბსტრაქტი

246. Mathieu C, Ásbjörnsdóttir B, Bajaj HS, et al. Switching to once-weekly insulin icodec versus once-daily insulin glargine U100 in individuals with basal-bolus insulin-treated type 2 diabetes (ONWARDS 4): a phase 3a, randomised, open-label, multicentre, treat-to-target, non-inferiority trial. Lancet. 2023 Jun 10;401(10392):1929-40.სრული ტექსტი  აბსტრაქტი

247. Lingvay I, Asong M, Desouza C, et al. Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes: rhe ONWARDS 3 randomized clinical trial. JAMA. 2023 Jul 18;330(3):228-37.სრული ტექსტი  აბსტრაქტი

248. Rosenstock J, Bain SC, Gowda A, et al. Weekly Icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med. 2023 Jul 27;389(4):297-308.სრული ტექსტი  აბსტრაქტი

249. Bajaj HS, Aberle J, Davies M, et al. Once-weekly insulin icodec with dosing guide app versus once-daily basal insulin analogues in insulin-naive type 2 diabetes (ONWARDS 5): a randomized trial. Ann Intern Med. 2023 Sep 26.სრული ტექსტი  აბსტრაქტი

250. Bue-Valleskey JM, Kazda CM, Ma C, et al. Once-weekly basal insulin Fc demonstrated similar glycemic control to once-daily insulin degludec in insulin-naive patients with type 2 diabetes: a phase 2 randomized control trial. Diabetes Care. 2023 May 1;46(5):1060-7.სრული ტექსტი  აბსტრაქტი

251. Matthews DR, Paldánius PM, Proot P, et al. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019 Oct 26;394(10208):1519-29.სრული ტექსტი  აბსტრაქტი

252. Mohan V, Zargar A, Chawla M, et al. Efficacy of a combination of metformin and vildagliptin in comparison to metformin alone in type 2 diabetes mellitus: a multicentre, retrospective, real-world evidence study. Diabetes Metab Syndr Obes. 2021;14:2925-33.სრული ტექსტი  აბსტრაქტი

253. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-55.სრული ტექსტი  აბსტრაქტი

254. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021 Aug 5;385(6):503-15.სრული ტექსტი  აბსტრაქტი

255. Frias JP, Nauck MA, Van J, et al. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial. Lancet. 2018 Nov 17;392(10160):2180-93.სრული ტექსტი  აბსტრაქტი

256. Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022 Sep;10(9):623-33.სრული ტექსტი  აბსტრაქტი

257. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021 Aug 14;398(10300):583-98.სრული ტექსტი  აბსტრაქტი

258. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021 Nov 13;398(10313):1811-24.სრული ტექსტი  აბსტრაქტი

259. ClinicalTrials.gov. ​Safety and efficacy of bexagliflozin as monotherapy in patients with type 2 diabetes. June 2021 [internet publication].სრული ტექსტი

260. ClinicalTrials.gov. ​Safety and efficacy of bexagliflozin compared to placebo as add-on therapy to metformin in type 2 diabetes subjects. July 2021 [internet publication].სრული ტექსტი

261. ClinicalTrials.gov. Safety and efficacy of bexagliflozin compared to glimepiride as add-on therapy to metformin in type 2 diabetes subjects. May 2021 [internet publication].სრული ტექსტი

262. ClinicalTrials.gov. Safety and efficacy of bexagliflozin compared to sitagliptin as add-on therapy to metformin in type 2 diabetes subjects. June 2021 [internet publication].​სრული ტექსტი

263. ClinicalTrials.gov. Safety and efficacy of bexagliflozin in type 2 diabetes mellitus patients with moderate renal impairment. June 2021 [internet publication].​სრული ტექსტი

264. ClinicalTrials.gov. Bexagliflozin efficacy and safety trial (BEST). July 2021 [internet publication].​სრული ტექსტი

265. Halvorsen YD, Lock JP, Zhou W, et al. A 24-week, randomized, double-blind, active-controlled clinical trial comparing bexagliflozin with sitagliptin as an adjunct to metformin for the treatment of type 2 diabetes in adults. Diabetes Obes Metab. 2019 Oct;21(10):2248-56.სრული ტექსტი  აბსტრაქტი

266. Allegretti AS, Zhang W, Zhou W, et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am J Kidney Dis. 2019 Sep;74(3):328-37.სრული ტექსტი  აბსტრაქტი

267. Halvorsen YD, Conery AL, Lock JP, et al. Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: a 24-week, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2023 Oct;25(10):2954-62.სრული ტექსტი  აბსტრაქტი

268. Cefalo CMA, Cinti F, Moffa S, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019 Feb 28;18(1):20.სრული ტექსტი  აბსტრაქტი

269. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021a Jan 14;384(2):129-39.სრული ტექსტი  აბსტრაქტი

270. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021b Jan 14;384(2):117-28.სრული ტექსტი  აბსტრაქტი

271. National Institute for Health and Care Excellence. Bempedoic acid with ezetimibe for treating primary hypercholesterolaemia or mixed dyslipidaemia. April 2021 [internet publication].სრული ტექსტი

272. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023 Apr 13;388(15):1353-64.სრული ტექსტი  აბსტრაქტი

273. Tomic D, Morton JI, Chen L, et al. Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study. Lancet Diabetes Endocrinol. 2022 Nov;10(11):795-803.სრული ტექსტი  აბსტრაქტი

274. Raghavan S, Vassy JL, Ho YL, et al. Diabetes mellitus-related all-cause and cardiovascular mortality in a national cohort of adults. J Am Heart Assoc. 2019 Feb 19;8(4):e011295.სრული ტექსტი  აბსტრაქტი

275. Harding JL, Pavkov ME, Magliano DJ, et al. Global trends in diabetes complications: a review of current evidence. Diabetologia. 2019 Jan 31;62(1):3-16.სრული ტექსტი  აბსტრაქტი

276. Ockrim Z, Yorston D. Managing diabetic retinopathy. BMJ. 2010 Oct 25;341:c5400. აბსტრაქტი

277. Thomas RL, Dunstan FD, Luzio SD, et al. Prevalence of diabetic retinopathy within a national diabetic retinopathy screening service. Br J Ophthalmol. 2015 Jan;99(1):64-8. აბსტრაქტი

278. Burrows NR, Hora I, Geiss LS, et al. Incidence of end-stage renal disease attributed to diabetes among persons with diagnosed diabetes - United States and Puerto Rico, 2000-2014. MMWR Morb Mortal Wkly Rep. 2017 Nov 3;66(43):1165-70.სრული ტექსტი  აბსტრაქტი

279. Riddle MC, Cefalu WT, Evans PH, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021 Aug 30;44(10):2438-44.სრული ტექსტი  აბსტრაქტი

280. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America. This statement does not represent an update of the 2017 ACC/AHA/HFSA heart failure guideline update. Circulation. 2019 Aug 13;140(7):e294-324.სრული ტექსტი  აბსტრაქტი

281. Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart failure: an underappreciated complication of diabetes. A consensus report of the American Diabetes Association. Diabetes Care. 2022 Jul 7;45(7):1670-90.სრული ტექსტი  აბსტრაქტი

282. Nichols GA, Gullion CM, Koro CE, et al. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004 Aug;27(8):1879-84. აბსტრაქტი

283. Barrett-Connor EL, Cohn BA, Wingard DL, et al. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA. 1991 Feb 6;265(5):627-31. აბსტრაქტი

284. Simpson TC, Weldon JC, Worthington HV, et al. Treatment of periodontal disease for glycaemic control in people with diabetes mellitus. Cochrane Database Syst Rev. 2022 Apr 14;4(4):CD004714.სრული ტექსტი  აბსტრაქტი

285. Bascones-Martinez A, Matesanz-Perez P, Escribano-Bermejo M, et al. Periodontal disease and diabetes: review of the literature. Med Oral Patol Oral Cir Bucal. 2011 Sep 1;16(6):e722-9.სრული ტექსტი  აბსტრაქტი

286. Pathak RD, Schroeder EB, Seaquist ER, et al. Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005-2011. Diabetes Care. 2016 Mar;39(3):363-70. აბსტრაქტი

287. Davis SN, Umpierrez GE. Diabetic ketoacidosis in type 2 diabetes mellitus - pathophysiology and clinical presentation. Nat Clin Pract Endocrinol Metab. 2007 Nov;3(11):730-1. აბსტრაქტი

288. Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009 Jul;32(7):1335-43.სრული ტექსტი  აბსტრაქტი

289. Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019 Oct;7(10):776-85. აბსტრაქტი

290. Ruta LM, Magliano DJ, Lemesurier R, et al. Prevalence of diabetic retinopathy in type 2 diabetes in developing and developed countries. Diabet Med. 2013 Apr;30(4):387-98. აბსტრაქტი

291. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond). 2015 Sep 30;2:17.სრული ტექსტი  აბსტრაქტი

292. Yau JW, Rogers SL, Kawasaki R, et al; Meta-Analysis for Eye Disease (META-EYE) Study Group. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012 Mar;35(3):556-64.სრული ტექსტი  აბსტრაქტი

293. Hoffstad O, Mitra N, Walsh J, et al. Diabetes, lower-extremity amputation, and death. Diabetes Care. 2015 Oct;38(10):1852-7.სრული ტექსტი  აბსტრაქტი

294. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017 Jan;40(1):136-54.სრული ტექსტი  აბსტრაქტი

295. Rustad JK, Musselman DL, Nemeroff CB. The relationship of depression and diabetes: pathophysiological and treatment implications. Psychoneuroendocrinology. 2011 Oct;36(9):1276-86. აბსტრაქტი

296. Ke C, Lau E, Shah BR, et al. Excess burden of mental Illness and hospitalization in young-onset type 2 diabetes: a population-based cohort study. Ann Intern Med. 2019 Feb 5;170(3):145-54. აბსტრაქტი

297. Pamidi S, Tasali E. Obstructive sleep apnea and type 2 diabetes: is there a link? Front Neurol. 2012 Aug 13;3:126.სრული ტექსტი  აბსტრაქტი

298. Shaw JE, Punjabi NM, Naughton MT, et al. The effect of treatment of obstructive sleep apnea on glycemic control in type 2 diabetes. Am J Respir Crit Care Med. 2016 Aug 15;194(4):486-92. აბსტრაქტი

299. Martínez-Cerón E, Barquiel B, Bezos AM, et al. Effect of continuous positive airway pressure on glycemic control in patients with obstructive sleep apnea and type 2 diabetes: a randomized clinical trial. Am J Respir Crit Care Med. 2016 Aug 15;194(4):476-85. აბსტრაქტი

300. Thomassen JQ, Tolstrup JS, Benn M, et al. Type-2 diabetes and risk of dementia: observational and Mendelian randomisation studies in 1 million individuals. Epidemiol Psychiatr Sci. 2020 Apr 24;29:e118.სრული ტექსტი  აბსტრაქტი

301. Chatterjee S, Peters SA, Woodward M, et al. Type 2 diabetes as a risk factor for dementia in women compared with men: a pooled analysis of 2.3 million people comprising more than 100,000 cases of dementia. Diabetes Care. 2016 Feb;39(2):300-7.სრული ტექსტი  აბსტრაქტი

302. Ninomiya T. Diabetes mellitus and dementia. Curr Diab Rep. 2014;14(5):487. აბსტრაქტი

303. Celis-Morales CA, Franzén S, Eeg-Olofsson K, et al. Type 2 diabetes, glycemic control, and their association with dementia and its major subtypes: findings from the Swedish National Diabetes Register. Diabetes Care. 2022 Mar 1;45(3):634-41.სრული ტექსტი  აბსტრაქტი

304. Zheng B, Su B, Price G, et al. Glycemic control, diabetic complications, and risk of dementia in patients with diabetes: results from a large U.K. Cohort study. Diabetes Care. 2021 Jul;44(7):1556-63.სრული ტექსტი  აბსტრაქტი

305. Moran C, Lacy ME, Whitmer RA, et al. Glycemic control over multiple decades and dementia risk in people with type 2 diabetes. JAMA Neurol. 2023 Jun 1;80(6):597-604. აბსტრაქტი

306. Public Health England. Diabetic eye screening: programme overview. May 2021 [internet publication].სრული ტექსტი

307. GOV.UK. Metformin and reduced vitamin B12 levels: new advice for monitoring patients at risk​. June 2022 [internet publication].სრული ტექსტი

308. Norris SL, Nichols PJ, Caspersen CJ, et al. Increasing diabetes self-management education in community settings: a systematic review. Am J Prev Med. 2002 May;22(suppl 4):39-66. აბსტრაქტი

309. Powers MA, Bardsley J, Cypress M, et al. Diabetes self-management education and support in type 2 diabetes: a joint position statement of the American Diabetes Association, the American Association of Diabetes Educators, and the Academy of Nutrition and Dietetics. Diabetes Care. 2015 Jul;38(7):1372-82.სრული ტექსტი  აბსტრაქტი

310. Prochaska JO, Velicer WF, Rossi JS, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol. 1994 Jan;13(1):39-46. აბსტრაქტი

311. Young LA, Buse JB, Weaver MA, et al; Monitor Trial Group. Glucose self-monitoring in non-insulin-treated patients with type 2 diabetes in primary care settings: a randomized trial. JAMA Intern Med. 2017 Jul 1;177(7):920-9. აბსტრაქტი

312. Malanda UL, Welschen LM, Riphagen II, et al. Self monitoring of blood glucose in patients with type 2 diabetes mellitus who are not using insulin. Cochrane Database Syst Rev. 2012 Jan 18;(1):CD005060.სრული ტექსტი  აბსტრაქტი

313. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003 Jan 30;348(5):383-93.სრული ტექსტი  აბსტრაქტი

314. UK Health Security Agency. Influenza: the green book, chapter 19. September 2022 [internet publication].სრული ტექსტი

315. UK Health Security Agency. Pneumococcal: the green book, chapter 25. August 2023 [internet publication].სრული ტექსტი

316. UK Health Security Agency. ​COVID-19: the green book, chapter 14a. September 2023 [internet publication].სრული ტექსტი